ACTRN12623001064695招募中2 期
A Double-Blind Randomised Controlled Trial of the Efficacy of Microdosing with Psilocybin to treat Moderate Depression
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 293
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants may be included in the study if they meet all of the following inclusion criteria.
- •1.Age greater than or equal to 18 years at the time of screening
- •2.Self-reported fluency in English
- •3.Meets the definition of moderate depression, defined as a score of between 15 and 23 on the Hamilton Rating Scale for Depression
- •4.Diagnosis of major depressive disorder, as assessed by the Mini International Neuropsychiatric Interview (MINI)
- •5.Able to swallow WP001 or Caffeine capsules
- •6.Has a body weight between 50kg and 120kg, and BMI above 16.
- •7.Refrains from the use of any psychoactive medication not approved by the research team from baseline through Study Termination.
- •8.Agrees to abstain from herbal, complementary or over the counter medications with serotonergic effects including, but not limited to, St John’s Wort, S-adenosyl methionine (SAM-e), 5-hydroxytryptophan (5-HTP) and L-tryptophan.
- •9.Agrees to comply with contraception requirements:
- •a.Women of childbearing potential must have a negative urine or serum pregnancy test at screening and baseline and be non-lactating. During the study, women of childbearing potential must agree to use a highly effective method of birth control up to 7 days after the last dose.
- •b.Male participants must agree to use highly effective method of birth control during the participation in the study up to 7 days after the last dose.
- •10.Able and willing to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures
- •11.Agrees to study investigators communicating directly with all of their External Health Practitioners.
- •12.Provides a contact (relative, spouse, close friend or other Support Person) who is willing and able to be reached by the investigators in the event of a participant becoming unreachable.
- •13.Must agree not to operate heavy machinery, any motorised vehicle or perform tasks that might endanger oneself or others, such as those requiring fine motor control, fast response times or real-time planning for three hours following each dosing session.
排除标准
- •Participants will be excluded from the study if they meet any of the following exclusion criteria:
- •1.Recently started new psychological therapies and/or sessions with health professionals within 30 days of consent (such as counsellor, psychotherapists). Participants with a stable regimen may be included in this study if they agree to continue with the psychological therapies and/or counselling sessions as is (frequency of the therapy and/or sessions should not change)
- •2.Use of antidepressant or antipsychotic medication in the prior 3 months, or plans to start new antidepressant or antipsychotic medication in the upcoming 2 months
- •3.Current diagnosis of psychotic disorder, bipolar disorder, personality disorder, post-traumatic stress disorder, or substance use disorders.
- •4.Identification of a primary mental health diagnosis apart from Major Depressive Disorder on the Mini International Neuropsychiatric Interview.
- •5.Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to Columbia Suicide Severity Rating Scale (C-SSRS), and clinical judgment of the investigator will be excluded. Any participant who is likely to require hospitalisation related to suicidal ideation and behaviour, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the screening C-SSRS will be excluded:
- •1.Suicidal ideation score of 4 or greater within the last month of the assessment at any frequency.
- •2.Suicidal ideation score of 4 or greater within the last 12 months of the assessment at a frequency of once a month or more.
- •3.Any suicidal preparatory acts or preparatory behaviour, within the last 12 months of the assessment. Participants with non-suicidal self-injurious behaviour may be included if approved by the CI.
- •4.Any suicidal behaviour, including actual, aborted, or interrupted suicide attempts within lifetime.
- •5.Would present a serious risk to others as established through clinical interview and contact with External Health Practitioners.
- •6.Require ongoing concomitant therapy with a psychiatric medication for management.
- •6.Poorly controlled hypertension or other cardiac abnormalities.
- •7.History of psychosis, bipolar disorder, stroke, epilepsy, brain injury or head trauma.
- •8.History of serious liver (Child-Pugh B or C), kidney disease (eGFR<60ml/min).
- •9.First degree relative with psychotic disorder.
- •10.Pregnant, or trying to get pregnant, or breastfeeding
- •11.Use of any psychotropic drug (excluding alcohol, nicotine and caffeine) within the last 3 months from date of consent
- •12.Moderate to severe cannabis or alcohol use disorder in the prior 12 months
- •13.An illicit or prescription drug use disorder of any severity in the prior 12 months
- •14.Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- •15.Significantly abnormal laboratory blood test defined as outside the normal range and deemed clinically significant by an investigator with expertise in this field
- •16.Resting blood pressure exceeding 160mmHg systolic and 100mmHg diastolic
- •17.Currently taking part in another clinical trial involving interventions such as an investigational drug, device, or psychotherapy
- •18.Current evidence of, or a history of, any condition, therapy or abnormal laboratory assessment or other events that, in the opinion of the investigator, may affec
研究者
相似试验
已完成
不适用
A Double Blind, Randomised Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid SurgeryEfficacy of pain control in patient undergone Open thyroid or parathyroid surgeryRandomised controlled trialWound infiltrationBupivacaineDiclofenacthyroid surgeryparathyroid surgeryTCTR20180925008Self Sponsored94
已完成
4 期
Comparing Salivary Levels of TNF alpha in Patients with Oral Lichen Planus Treated with Topical Clobetasol Propionate and Fluocinolone Acetonidepatients with oral lichen planusOral Lichen Planus, Clobetasol Propionate, Fluocinolone Acetonide, Topical steroid,TNF alphaTCTR20220705003Faculty of Dentistry Chiang Mai university ,Chiang Mai, Thailand26
招募中
1 期
Intraoperative pillar corticosteroid injection Does it improve the patient satisfaction after carpal tunnel surgery? Randomized controlled trial, Double blind studyPillar corticosteroid injectionCarpal tunnel releasePillar painCarpal tunnel syndromeTCTR20211130003Chakrinaruebodindra medical institute84
Enrolling By Invitation
1 期
Efficacy of night splint position in Giovanni position compare with Traditional position on acute plantar fasciitis treatmentight splint is the treatment options in patient with acute plantar fasciitis that is not improve with conservative treatmentNight splint, traditional position, digiovanni position, fiberglass night splintTCTR20220310001Faculty of Medicine, Prince of Songkla University48
尚未招募
3 期
Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors.CTRI/2020/12/030115The Terry Fox International Research